Blood CD62L low inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab
Allergy · 2023-12 · 78 (12) · 3154-3165
DOI: 10.1111/all.15909 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, online erschienen am 04.10.2023. Verfasst von Alessandra Vultaggio und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Asthma, Pulmonary Eosinophilia, Anti-Asthmatic Agents. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background
Eosinophils have been divided into different subpopulations with distinct phenotypes based on CD62L expression. No data are available regarding the correlation between eosinophils subphenotypes and clinical severity of asthma, as well as the effect of anti‐IL‐5 therapy on these cells. The study investigates the correlation between blood CD62L low inflammatory eosinophils (iEos) and clinical severity of severe eosinophilic asthma (SEA) and evaluates the impact of mepolizumab on iEos.
Methods
112 patients were screened and were divided in two groups: biological‐naive ( n = 51) and biological‐treated patients ( n = 61). The Biological‐naive patients were analyzed before treatment (Group A) and 19 out of 51 patients, were longitudinally analyzed before and after treatment with mepolizumab 100 mg s.c/4 weeks (Group B); 32 patients were excluded because they were being treated with other biological therapies. Blood eosinophils were analyzed by FACS and correlated with clinical scores. In vitro effect of IL‐5 and mepolizumab on CD62L expression was assessed.
Results
A significant correlation between blood CD62L low cells and clinical scores of asthma and nasal polyps, as well as the number of asthma exacerbations in the last year was shown in untreated patients. In longitudinally studied patients we observed a marked reduction of CD62L low cells paralleled by an increase in the proportion of CD62L bright cells, associated with clinical improvement of asthma control. In vitro, CD62L expression on eosinophils is modulated by IL‐5 and anti‐IL‐5.
Conclusion
A positive correlation between CD62L low iEos and the baseline clinical features of SEA with CRSwNP was shown. Furthermore mepolizumab restores the healthy balance among eosinophils sub‐phenotypes in SEA patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
- Immunology and Cellular Therapy Unit, Careggi University Hospital, Florence, Italy.
- Department of Clinical and Experimental Medicine, Otolaryngology Clinic, University of Florence, Florence, Italy.
- Immunoallergology Unit, Careggi University Hospital, Florence, Italy.
- Translational Immunology Unit, Immunology Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
ORCID-Profile: Enrico Maggi, Oreste Gallo, Andrea Matucci
Zitieren
APA
Vultaggio, A., Accinno, M., Vivarelli, E., Mecheri, V., Maggiore, G., Cosmi, L., Parronchi, P., Rossi, O., Maggi, E., Gallo, O., & Matucci, A. (2023). Blood CD62L low inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab. Allergy, 78(12), 3154-3165. https://doi.org/10.1111/all.15909
Vancouver
Vultaggio A, Accinno M, Vivarelli E, Mecheri V, Maggiore G, Cosmi L, et al. Blood CD62L low inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab. Allergy. 2023;78(12):3154-3165. doi:10.1111/all.15909
BibTeX
@article{Vultaggio2023,
author = {Vultaggio, Alessandra and Accinno, Matteo and Vivarelli, Emanuele and Mecheri, Valentina and Maggiore, Giandomenico and Cosmi, Lorenzo and Parronchi, Paola and Rossi, Olivero and Maggi, Enrico and Gallo, Oreste and Matucci, Andrea},
title = {Blood CD62L low inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab},
journal = {Allergy},
year = {2023},
volume = {78},
number = {12},
pages = {3154--3165},
doi = {10.1111/all.15909}
}
EUVIMED